Cell Surface Markers Market To Reach USD 965.0 Million By 2026 | Reports And Data
July 18, 2019 10:33 ET
|
Reports and Data
New York, July 18, 2019 (GLOBE NEWSWIRE) -- The technological advancements in the health care sector, increased in rate of occurrence of cancer, and rise in investment in research and developments...
Lans Holdings Enters into Binding LOI to Acquire Global Stem Cells Group
May 28, 2019 08:00 ET
|
Lans Holdings Inc.
MIAMI, FL, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Lans Holdings Inc. (OTCPink: LAHO) is pleased to announce that it has entered into a binding letter of intent to acquire 100%...
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019
May 17, 2019 08:30 ET
|
International Stem Cell Corporation
CARLSBAD, Calif., May 17, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
3D Cell Culture Market To Reach USD 1.99 Billion By 2026 | Reports And Data
April 25, 2019 13:24 ET
|
Reports And Data
The government and non-government investments in cancer research & development, coupled with the large scale end uses of stem cell research are influencing the market growth. Market Size – USD...
International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results
April 15, 2019 08:30 ET
|
International Stem Cell Corporation
CARLSBAD, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
Hemostemix Announces Appointment of Experienced Chief Medical Officer & President
April 01, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D,...
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
February 25, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
Hemostemix Provides Highlights of 2018 Accomplishments
January 17, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on...
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
January 03, 2019 08:00 ET
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
November 09, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...